文献速递淋巴瘤

经典型霍奇金淋巴瘤中JAK-STAT通路基因的广泛突变

Pervasive mutations of JAK-STAT pathway genes in classical Hodgkin lymphoma.
PubMed 文献 · Blood · 2018-04-12

本研究对34例经典型霍奇金淋巴瘤(cHL)患者活检标本进行显微切割,分离约5万个单个淋巴瘤细胞并分析其编码基因组。发现STAT6(32%)、GNA13(24%)、XPO1(18%)和ITPKB(16%)等复发突变,并证实突变STAT6维持肿瘤细胞存活;87%病例存在JAK-STAT通路多基因异常,提示该通路是cHL发病关键及潜在治疗靶点。

要点

  • cHL肿瘤细胞稀少(通常<5%),本研究通过显微切割34例活检中约5万个细胞分析编码基因组。
  • 复发突变基因包括STAT6(32%)、GNA13(24%)、XPO1(18%)和ITPKB(16%)。
  • 87%病例存在JAK-STAT通路多基因异常,突变STAT6与SOCS1破坏协同促进cHL生长。

核心结论

  • cHL中JAK-STAT通路基因广泛突变,87%病例存在该通路异常,提示其在发病中起关键作用并可能成为新治疗靶点。

研究设计与样本

  • 对34例cHL患者活检标本的肿瘤细胞和正常细胞进行显微切割,共分离约5万个单个淋巴瘤细胞并分析编码基因组。

主要发现

  • 复发突变基因包括STAT6(32%病例)、GNA13(24%)、XPO1(18%)和ITPKB(16%)。
  • 突变STAT6在维持肿瘤细胞存活中具有功能作用,并与SOCS1(JAK-STAT通路抑制因子)破坏在遗传和功能上协同促进cHL生长。
  • 87%病例通过多基因(还包括STAT3、STAT5B、JAK1、JAK2和PTPN1)遗传改变显示JAK-STAT通路失调。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Dissecting the pathogenesis of classical Hodgkin lymphoma (cHL), a common cancer in young adults, remains challenging because of the rarity of tumor cells in involved tissues (usually <5%). Here, we analyzed the coding genome of cHL by microdissecting tumor and normal cells from 34 patient biopsies for a total of ∼50 000 singly isolated lymphoma cells. We uncovered several recurrently mutated genes, namely, STAT6 (32% of cases), GNA13 (24%), XPO1 (18%), and ITPKB (16%), and document the functional role of mutant STAT6 in sustaining tumor cell viability. Mutations of STAT6 genetically and functionally cooperated with disruption of SOCS1, a JAK-STAT pathway inhibitor, to promote cHL growth. Overall, 87% of cases showed dysregulation of the JAK-STAT pathway by genetic alterations in multiple genes (also including STAT3, STAT5B, JAK1, JAK2, and PTPN1), attesting to the pivotal role of this pathway in cHL pathogenesis and highlighting its potential as a new therapeutic target in this disease.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Tiacci E, Ladewig E, Schiavoni G, et al. Pervasive mutations of JAK-STAT pathway genes in classical Hodgkin lymphoma. Blood. 2018. PMID: 29650799. doi:10.1182/blood-2017-11-814913

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。